Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023487
Disease: Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
0.030 Biomarker disease BEFREE AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. 21385856 2011
CUI: C0023487
Disease: Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
0.030 GeneticVariation disease BEFREE We investigated the prevalence and clinico-biological correlations of FLT3 ITDs and D835 mutations in 90 patients with acute promyelocytic leukemia (APL) receiving the AIDA protocol. 12399960 2002
CUI: C0023487
Disease: Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
0.030 Biomarker disease BEFREE Our findings indicate that APL patients who are molecularly resistant to the AIDA protocol have no distinguishing features at presentation. 14754603 2004
ST segment elevation myocardial infarction
0.030 Biomarker disease BEFREE CMR-FT is a superior measure of LV function and performance early after reperfused MI with incremental prognostic value for mortality over and above LV ejection fraction and infarct size.(Abciximab i.v.Versus i.c. in ST-segment elevation Myocardial Infarction [AIDA STEMI]; NCT00712101; Thrombus Aspiration in ThrOmbus Containing culpRIT Lesions in Non-ST-Elevation Myocardial Infarction [TATORT-NSTEMI]; NCT01612312). 29454776 2018
ST segment elevation myocardial infarction
0.030 Biomarker disease BEFREE Materials and Methods This secondary analysis of two prospective multicenter cardiac MRI studies (AIDA STEMI [NCT00712101] and TATORT NSTEMI [NCT01612312]) included 1235 study participants with ST-elevation myocardial infarction (<i>n</i> = 795) or non-ST-elevation myocardial infarction (<i>n</i> = 440) between July 2008 and June 2013. 31526253 2019
ST segment elevation myocardial infarction
0.030 GeneticVariation disease BEFREE STEMI patients ( n=738) included in the AIDA STEMI trial underwent primary percutaneous coronary intervention within 12 hours after symptom onset. 26691729 2017
CUI: C0010054
Disease: Coronary Arteriosclerosis
Coronary Arteriosclerosis
0.020 GeneticVariation disease BEFREE Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: A substudy of the AIDA STEMI trial. 26691729 2017
CUI: C0010054
Disease: Coronary Arteriosclerosis
Coronary Arteriosclerosis
0.020 Biomarker disease BEFREE Integrative analysis of vascular endothelial cell genomic features identifies AIDA as a coronary artery disease candidate gene. 31287004 2019
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease
0.020 Biomarker disease BEFREE Integrative analysis of vascular endothelial cell genomic features identifies AIDA as a coronary artery disease candidate gene. 31287004 2019
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease
0.020 GeneticVariation disease BEFREE Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: A substudy of the AIDA STEMI trial. 26691729 2017
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease
0.020 AlteredExpression disease BEFREE We validate one CAD locus, by engineering a deletion of the TNFα-sensitive regulatory element using CRISPR/Cas9 and measure the effect on the expression of the novel CAD candidate gene AIDA. 31287004 2019
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease
0.020 GeneticVariation disease BEFREE Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: A substudy of the AIDA STEMI trial. 26691729 2017
Non-ST Elevated Myocardial Infarction
0.020 Biomarker disease BEFREE CMR-FT is a superior measure of LV function and performance early after reperfused MI with incremental prognostic value for mortality over and above LV ejection fraction and infarct size.(Abciximab i.v.Versus i.c. in ST-segment elevation Myocardial Infarction [AIDA STEMI]; NCT00712101; Thrombus Aspiration in ThrOmbus Containing culpRIT Lesions in Non-ST-Elevation Myocardial Infarction [TATORT-NSTEMI]; NCT01612312). 29454776 2018
Non-ST Elevated Myocardial Infarction
0.020 Biomarker disease BEFREE Materials and Methods This secondary analysis of two prospective multicenter cardiac MRI studies (AIDA STEMI [NCT00712101] and TATORT NSTEMI [NCT01612312]) included 1235 study participants with ST-elevation myocardial infarction (<i>n</i> = 795) or non-ST-elevation myocardial infarction (<i>n</i> = 440) between July 2008 and June 2013. 31526253 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.010 Biomarker disease BEFREE CMR-FT is a superior measure of LV function and performance early after reperfused MI with incremental prognostic value for mortality over and above LV ejection fraction and infarct size.(Abciximab i.v.Versus i.c. in ST-segment elevation Myocardial Infarction [AIDA STEMI]; NCT00712101; Thrombus Aspiration in ThrOmbus Containing culpRIT Lesions in Non-ST-Elevation Myocardial Infarction [TATORT-NSTEMI]; NCT01612312). 29454776 2018
CUI: C0028754
Disease: Obesity
Obesity
0.010 Biomarker disease BEFREE AIDA Selectively Mediates Downregulation of Fat Synthesis Enzymes by ERAD to Retard Intestinal Fat Absorption and Prevent Obesity. 29617643 2018
CUI: C0028879
Disease: Odontogenic Cysts
Odontogenic Cysts
0.010 Biomarker disease BEFREE Immunohistochemical validation of chosen putative biomarkers revealed axin interaction partner and dorsalization-antagonist (AIDA), known as a protein that blocks activation of JNK signalling pathway, as a differential biomarker for KCOT lesions on an independent cohort of KCOT tissue samples in comparison with most prevalent intra-oseal lesions inflammatory odontogenic cysts. 25040847 2015
CUI: C0028880
Disease: Odontogenic Tumors
Odontogenic Tumors
0.010 Biomarker group BEFREE Immunohistochemical validation of chosen putative biomarkers revealed axin interaction partner and dorsalization-antagonist (AIDA), known as a protein that blocks activation of JNK signalling pathway, as a differential biomarker for KCOT lesions on an independent cohort of KCOT tissue samples in comparison with most prevalent intra-oseal lesions inflammatory odontogenic cysts. 25040847 2015
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.010 Biomarker disease BEFREE Moreover, <i>aidA</i> expression in the first type of strain was not regulated in the presence of environmental stress factors such as the 3-oxo-C12-HSL molecule (substrate of AidA protein, QQ activation) or H<sub>2</sub>O<sub>2</sub> (inhibitor of AidA protein, QS activation).However, in the <i>A. baumannii</i> strains isolated from patients with non-bacteraemic pneumonia, <i>aidA</i> gene expression was regulated by stressors such as 3-oxo-C12-HSL and H<sub>2</sub>O<sub>2</sub>. 30619184 2018
Childhood Acute Promyelocytic Leukemia with PML-RARA
0.010 Biomarker disease BEFREE These results highlight the efficacy and feasibility of the AIDA protocol in the pediatric APL population. 15677559 2005
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental
0.300 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014